Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imatinib in Idiopathic Pulmonary Fibrosis
NCT00131274Phase 3Completed
- Start
- Apr 2003
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in idiopathic pulmonary fibrosis (IPF) comparing Imatinib Mesylate with Placebo (2 arms). Primary endpoint: Disease Progression or Death at 96 weeks. Started Apr 2003; status: completed.
02
Drugs
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT00131274.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00131274.